Stocktoria
Immunome Inc. IMNM
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-02
Immunome Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | — | — | — | — |
| R&D expense | $177.3M | $129.5M | $23.1M | $23.3M | $14.1M | $7.5M | $8.8M |
| Operating income | -$224.1M | -$305.8M | -$109.5M | -$36.9M | -$25.2M | -$12.3M | -$10.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$212.4M | -$293.0M | -$106.8M | -$36.9M | -$24.7M | -$17.8M | -$10.4M |
| EPS (diluted) | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-5.26 | — |
| Operating cash flow | -$190.9M | -$110.8M | -$7.6M | -$28.7M | -$18.2M | -$12.1M | -$9.6M |
| Free cash flow | -$200.6M | -$118.0M | -$8.4M | -$28.9M | -$18.3M | -$12.7M | -$9.8M |
| Cash & equivalents | $653.5M | $143.4M | $98.7M | $20.3M | $49.2M | $39.8M | $2.5M |
| Total assets | $683.2M | $240.2M | $148.5M | $24.0M | $57.9M | $44.5M | $5.1M |
| Total liabilities | $48.8M | $59.1M | $28.7M | $7.4M | $9.7M | $3.2M | $1.8M |
| Shareholders' equity | $634.3M | $181.2M | $119.9M | $16.7M | $48.2M | $41.3M | -$35.6M |
Growth · year-over-year · Revenue CAGR -29.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -23.2% | -35.5% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.